Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 1, 2009, Pages 65-69

  Chen, Yi Hao ^a   Wu, Pei Chang ^a,b   Shiea, Jentaie ^c   Lo, Li Hua ^c   Wu, Yi Chen ^a   Kuo, Hsi Kung ^a,d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; VASCULOTROPIN 165;

ARTICLE; DRUG DEGRADATION; DRUG EFFICACY; DRUG STABILITY; DRUG STERILITY; DRUG STORAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG CONTAMINATION; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; OPHTHALMIC SOLUTIONS; STERILIZATION; TEMPERATURE; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 61749102290     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0043     Document Type: Article

References (12)

1. Mulcahy, M,F., and Benson, A.B., 3rd. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 5:997-1005, 2005.
2. Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:2335-2342, 2004.
3. Gordon, M.S., Margolin, K., Talpaz, M., et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19:843-850, 2001.
4. Avery, R.L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352-354, 2006.
5. Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372. e365, 2006.
6. Jorge, R., Costa, R.A., Calucci, D., et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26:1006-1013, 2006.
7. Bakri, S.J., Snyder, M.R., Pulido, J.S., et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 26:519-522, 2006.
8. Caprioli, R., Malomi, A., and Sidona G. Mass Spectrometry in Biomolecular Science, NATO ASI Ser. C. Dordrecht, the Netherlands: Kluwer, 1996.
9. Chapman, J.R. (Ed.). Protein and peptide analysis by mass spectrometry. In: Methods in Molecular Biology. Totowa, NJ: Humana Press, 1996.
10. Overberg, A., Hassenburger, A., and Hillenkamp, F. Laser desorption mass spectrometry. Part II: Performance and application of matrix-assisted laser desorption/ionization of large biomolecules. In: Gross, M., (Ed.), Mass Spectrometry in the Biological Sciences; A Tutorial. Dordrecht, the Netherlands: Kluwer, 1992.
11. Jonas, J.B., Spandau, U.H., Rensch, F., et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J. Ocul Pharmacol Ther. 23:240-242, 2007.
12. Beer, P.M., Wong, S.J., Hammad, A.M., et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26:871-876, 2006.